GIIS040-Grupo de Investigación en Hematología del HCU Lozano Blesa

Mateos M, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez M, Oriol A, Gutierrez N, Rios-Tamayo R, Rosinol L, Alvarez Rivas M, Bargay J, Gonzalez-Rodriguez A, Alegre A, Escalante F, Inigo Rodriguez M, de la Rubia J, Teruel A, de Arriba F, Palomera Bernal L, Hernandez M, Lopez Jimenez J, Reinoso-Segura M, Garcia Mateo A, Ocio E, Paiva B, Puig N, Cedena M, Blade J, Lahuerta J, San-Miguel J, Spanish Myeloma Grp GEM Pethema . Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO.23.02771. Q-1. F.I-41,9

Piñana J, López-Corral L, Martino R, Vazquez L, Pérez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave Rubio M, Corona M, Marcos-Corrales S, Tormo M, Hernández-Rivas J, Montoro J, Rodriguez-Fernandez A, Risco-Gálvez I, Rodríguez-Belenguer P, Hernandez-Boluda J, García-Cadenas I, Ruiz-García M, Muñoz-Bellido J, Solano C, Cedillo Á, Sureda A, Navarro D, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell  Tr . SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with  hematological disorders. Journal of Hematology & Oncology. 10.1186/s13045-022-01275-7. Q-1. F.I-40,4

Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R, Torres F, Fernandez-Cruz A, Calderon-Parra J, Payares-Herrera C, Diaz de Santiago A, Romera-Martinez I, Pintos I, Lora-Tamayo J, Mancheno-Losa M, Paciello M, Martinez-Gonzalez A, Vidan-Estevez J, Nunez-Orantos M, Isabel Saez-Serrano M, Porras-Leal M, Jarilla-Fernandez M, Villares P, Perez de Oteyza J, Ramos-Garrido A, Blanco L, Madrigal-Sanchez M, Rubio-Batlles M, Velasco-Iglesias A, Paño Pardo J, Moreno Chulilla J, Muniz-Diaz E, Casas-Flecha I, Perez-Olmeda M, Garcia-Perez J, Alcami J, Bueno J, Duarte R, ConPlas-19 Study Grp . A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia JOURNAL OF CLINICAL INVESTIGATION. 10.1172/JCI152740. Q-1. F.I-13,6

Luis Pinana J, Vazquez L, Calabuig M, Lopez-Corral L, Martin-Martin G, Villalon L, Sanz-Linares G, Conesa-Garcia V, Sanchez-Salinas A, Gago B, Facal A, Risco-Galvez I, Olave Rubio M, Espigado I, Lopez-Jimenez J, Angel Hernandez-Rivas J, Avendano-Pita A, Arroyo I, Ferrer E, Garcia-Cadenas I, Gonzalez-Santillana C, Roldan-Perez A, Ferrer B, Guerreiro M, Suarez-Lledo M, Camara A, Campos-Beltran D, Navarro D, Cedillo A, Sureda A, Solano C, Martino R, Spanish Hematopoietic Stem Cell Tr . One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients Blood Cancer Journal. 10.1038/s41408-022-00778-3. Q-1. F.I-11,6

Encinas C, Hernandez-Rivas J, Oriol A, Rosiñol L, Blanchard M, Bellón J, García-Sanz R, de la Rubia J, de la Guía A, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil Sahún M, de Arriba F, Pérez-Ávila C, Gonzalez Y, Hernández M, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez M, Sureda A, Sampol A, Ocio E, Krsnik I, García A, García-Mateo A, Soler J, Martín J, Arguiñano J, Mateos M, Bladé J, San-Miguel J, Lahuerta J, Martínez-López J, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica . A simple score to predict early severe infections in patients with newly  diagnosed multiple myeloma. Blood Cancer Journal. 10.1038/s41408-022-00652-2. Q-1. F.I-11,6

Luis Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave Rubio M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Angel Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Luis Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infect Complications Subcomm Spani . SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group AMERICAN JOURNAL OF HEMATOLOGY. 10.1002/ajh.26385. Q-1. F.I-10,3

Puig N, Agulló C, Contreras T, Pérez J, Aires I, Calasanz M, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González M, Oriol A, Gutiérrez N, Ríos-Tamayo R, Rosiñol L, Álvarez M, Bargay J, González-Rodríguez A, Alegre A, Escalante F, Iñigo M, De la Rubia J, Teruel A, De Arriba F, Palomera Bernal L, Hernández M, López-Jiménez J, Reinoso M, García-Mateo A, Ocio E, Bladé J, Lahuerta J, Cedena M, Paiva B, Miguel J, Mateos M. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial. HAEMATOLOGICA. 10.3324/haematol.2024.285742. Q-1. F.I-7,9

Puertas B, González-Calle V, Sureda A, Moreno M, Oriol A, González E, Rosiñol L, López J , Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez A, Dourdil Sahún M, De Arriba F, González S, Pérez-de-Oteyza J, Hernández M, García-Mateo A, Bargay J, Bladé J, Lahuerta J, San Miguel J, Ocio E, Mateos M. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. HAEMATOLOGICA. 10.3324/haematol.2022.282490. Q-1. F.I-7,9

Giraldos D, Galano-Frutos E, Cambronero Arregui L, Beltran Visiedo M, Romanos E, Reina-Ortiz C, Azaceta Reinares G, Martínez Lázaro B, Menéndez Jándula B, Garcia-Romero A, Jimenez-Albericio F, Marzo Rubio I, Naval J, Anel Bernal L. NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab OncoImmunology. 10.1080/2162402X.2025.2559782. Q-1. F.I-6,3

Serrano Del Valle A, Beltrán Visiedo M, De Poo Rodríguez V, Jiménez Alduán N, Azaceta Reinares G, Díez Angulo R, Martínez Lázaro B, Izquierdo García I, Palomera Bernal L, Naval Iraberri J, Anel Bernal L, Marzo Rubio I. Ecto-calreticulin expression in multiple myeloma correlates with a failed  anti-tumoral immune response and bad prognosis. OncoImmunology. 10.1080/2162402X.2022.2141973. Q-1. F.I-6,3